Jagsonpal Pharmaceuticals Limited

rs,

November 03, 2025 The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789 The Department of Corporate Services- Listing Na

10%

Jagsonpal Pharmaceuticals Ltd. announces Q2 & H1FY26 Results Robust H1 growth with 10% YoY uptick in Revenue & 39% PAT surge Gurugram, Nov 3, 2025: Jagsonpal Pharmaceuticals Limited (B

39%

maceuticals Ltd. announces Q2 & H1FY26 Results Robust H1 growth with 10% YoY uptick in Revenue & 39% PAT surge Gurugram, Nov 3, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM)

22.5%

Revenue Operating EBITDA* EBITDA Margin* PAT PAT Margin% H1FY26 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps

15.6%

rating EBITDA* EBITDA Margin* PAT PAT Margin% H1FY26 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2

22.8%

A Margin* PAT PAT Margin% H1FY26 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.

12.3%

T PAT Margin% H1FY26 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.

10.2%

H1FY26 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.9% 747 184

8.8%

6 H1FY25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.9% 747 184 24.6%

31 bps

25 1,501 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.9% 747 184 24.6% 115 1

39.2%

1 338 22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.9% 747 184 24.6% 115 15.3% Y

324 bps

22.5% 234 15.6% 1,361 310 22.8% 168 12.3% YoY% 10.2% 8.8% -31 bps 39.2% 324 bps Q2FY26 Q2FY25 745 181 24.3% 126 16.9% 747 184 24.6% 115 15.3% YoY % -0.

“The first half of FY26 marked a strong showing, with revenue rising 10% YoY to ₹1,501 Mn, EBITDA (pre-ESOP) grew 9% YoY to ₹338 Mn, and PAT witnessing a 39% YoY increase to ₹ 234 Mn.”

Lean Operations

1

Operations

1

Lean Operations

Asset Light Model Outsourced R&D and Manufacturing; built for growth without capital strain Backed by promoter conviction, long term vision Strategic alignment towards long term value creation 3 Q2 & H1FY26 Highlights 4 Management Commentary We are pleased to report a resilient performance reflecting our continued focus on sustainable growth and operational excellence. The first half of FY26 marked a strong showing, with revenue rising 10% YoY to ₹1,501 Mn, EBITDA (pre-ESOP) grew 9% YoY to ₹338 Mn, and PAT witnessing a 39% YoY increase to ₹ 234 Mn. This performance underscores our consistent execution, disciplined cost management, complementing the inherent strength of our diversified portfolio. We welcome GST 2.0- a step towards affordable healthcare. With our “Patient First” approach, we have fully passed the benefits through reduced prices. The transition led to temporary moderation in sales and trade movement. Despite this, revenue for Q2FY26 stood at ₹745 Mn, Operating EBITDA at ₹

Operations

Asset Light Model Inorganic Growth Powered by Strategic Acquisition 50+ Years Quality and Trust 16 Execution Excellence across all parameters 50+ Years Cash Rich and Growth Ready Capital Optimized for scalable growth Rewarding shareholders; Enhanced Payouts Quality and Trust 1,456 351 16.1% 252 FY22 139 6.7% FY25* FY22 FY24 93 3.5% FY25 Net Cash Position (₹ Mn) NWC (₹ Mn) % of sales 541 59 349 59 FY22 FY24 FY25 FCF (₹ Mn) *Net of ₹ 928 Mn spent on acquisition in FY25 13 FY22 FY25 NWCC (Days) 125 80 FY22 FY25 Dividend rate % 23% 900 bps 50% 1600 bps 14% 34% FY22 FY25 ROE ROCE 17 MySakhi Initiative Where Business Meets Social Impact Shaping the Future Empowering Women Through MySakhi.in 50+ Years Quality and Trust Expanding outreach with self-testing kits, discounted lab tests, and an online forum to support women’s holistic well-being. Driving Menopause Awareness Deliver impactful virtual sessions on menopause, supported by social media campaigns and community engagement. A dedicated we